Economic study of the value of expanding HCV treatment capacity in Germany.

ABSTRACT:

Background

Today's highly efficacious, low-toxicity interferon-free treatment regimens for chronic hepatitis C virus (HCV) can cure most patients with HCV in 12-24 weeks. The aim of this study was to understand how the introduction of shorter duration treatment regimens for HCV will impact the capacity for treatment and value to society.

Methods

A Markov model of HCV transmission and progression was constructed, incorporating nationally representative data on HCV prevalence, incidence and progression; mortality, treatment costs, medical expenditures, employment probabilities and disability payments in Germany. The model was stratified by HCV genotype and exposure route (1-time healthcare exposure, injection drug use and sexual activity). Treatment scenarios were based on Ger

SUBMITTER: Sbarigia U 

PROVIDER: S-EPMC5387957 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature